胰腺癌治疗的研究进展
Research Progress on the Treatment of Pancreatic Cancer
DOI: 10.12677/ACM.2019.95096, PDF,    科研立项经费支持
作者: 王君璞, 张 辉, 严 俊, 周文策：兰州大学第一临床医学院，甘肃 兰州
关键词: 胰腺癌；治疗；综述；Pancreatic Cancer； Treatment； Review
摘要: 胰腺癌是恶性程度极高的消化道肿瘤之一，其在全球的发病率和死亡率均在逐年升高。目前临床上治疗胰腺癌的方式主要包括手术切除、放化疗，由于胰腺癌发病隐匿、病情进展快、恶性程度高等特点，患者一经发现多处于癌症的中晚期，丧失手术机会，导致患者5年生存率不足6%。为延长患者生存时间，积极探索有效的治疗方法是目前胰腺癌亟待解决的问题。近年来，随着医疗事业的快速发展，胰腺癌的治疗方法从常规的手术、放化疗到生物碱药物治疗、基因治疗、免疫治疗等。本文就目前胰腺癌的治疗方式作一概述。
Abstract: Pancreatic cancer is one of the most malignant tumors of the digestive tract, and its global mor-bidity and mortality are increasing year by year. At present, the clinical treatment of pancreatic cancer mainly includes surgical resection, radiotherapy, chemotherapy, and combination of radi-otherapy and chemotherapy. Due to the concealed disease of pancreatic cancer, the disease pro-gresses rapidly, and the degree of malignancy is high. Once the patient is found to be in the middle and late stage of cancer, the operation is lost. Opportunities lead to a 5-year survival rate of less than 6%. In order to prolong the survival time of patients, actively exploring effective treatment methods is an urgent problem to be solved in pancreatic cancer. In recent years, with the rapid development of medical services, the treatment of pancreatic cancer has ranged from conventional surgery, radiotherapy and chemotherapy to alkaloid drug therapy, gene therapy, and immuno-therapy. This article provides an overview of current treatments for pancreatic cancer.
文章引用：王君璞, 张辉, 严俊, 周文策. 胰腺癌治疗的研究进展[J]. 临床医学进展, 2019, 9(5): 638-644. https://doi.org/10.12677/ACM.2019.95096

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. [Google Scholar] [CrossRef] [PubMed]
[3] Bosetti, C., Lucenteforte, E., Silverman, D.T., et al. (2012) Cigar and Pipe Smoking, Smokeless Tobacco Use and Pancreatic Cancer: An Analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Annals of Oncology, 23, 1880-1888. [Google Scholar] [CrossRef] [PubMed]
[4] Michaud, D.S., Giovannucci, E., Willett, W.C., et al. (2001) Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer. JAMA, 286, 921-929. [Google Scholar] [CrossRef] [PubMed]
[5] Gapstur, S.M., Jacobs, E.J., Deka, A., et al. (2011) Association of Alcohol Intake with Pancreatic Cancer Mortality in Never Smokers. Archives of Internal Medicine, 171, 444-451. [Google Scholar] [CrossRef] [PubMed]
[6] Bansal, P. and Sonnenberg, A. (1995) Pancreatitis Is a Risk Factor for Pancreatic Cancer. Gastroenterology, 109, 247-251. [Google Scholar] [CrossRef] [PubMed]
[7] Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., et al. (2005) Type-II Diabetes and Pancreatic Cancer: A Meta-Analysis of 36 Studies. British Journal of Cancer, 92, 2076-2083. [Google Scholar] [CrossRef] [PubMed]
[8] Giovannucci, E., Harlan, D.M., Archer, M.C., et al. (2010) Diabetes and Cancer: A Consensus Report. CA: A Cancer Journal for Clinicians, 60, 207-221. [Google Scholar] [CrossRef] [PubMed]
[9] Permuth Wey, J. and Egan, K.M. (2009) Family History Is a Significant Risk Factor for Pancreatic Cancer: Results from a Systematic Review and Meta-Analysis. Familial Cancer, 8, 109-117. [Google Scholar] [CrossRef] [PubMed]
[10] Fan, X., Alekseyenko, A.V., Wu, J., et al. (2018) Human Oral Microbiome and Prospective Risk for Pancreatic Cancer: A Population-Based Nested Case-Control Study. Gut, 67, 120-127. [Google Scholar] [CrossRef] [PubMed]
[11] 于文滨. 60例胰十二指肠切除手术治疗胰腺癌临床分析[J]. 中国现代药物应用, 2013, 7(5): 49-50.
[12] Ishikawa, O., Ohhigashi, H., Sasaki, Y., et al. (1988) Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head. Annals of Surgery, 208, 215-220. [Google Scholar] [CrossRef] [PubMed]
[13] Reddy, S.K., Tyler, D.S., Pappas, T.N., et al. (2007) Extended Resection for Pancreatic Adenocarcinoma. Oncologist, 12, 654-663. [Google Scholar] [CrossRef] [PubMed]
[14] Pedrazzoli, S. (2015) Extent of Lymphadenectomy to Associate with Pancreaticoduodenectomy in Patients with Pancreatic Head Cancer for Better Tumor Staging. Cancer Treatment Reviews, 41, 577-587. [Google Scholar] [CrossRef] [PubMed]
[15] Zhou, M., Cui, J.J., Wang, L.W., et al. (2017) Selection and Therapeutic Effect Evaluation of Chemotherapy Regimens for Pancreatic Cancer. Journal of Clinical Hepatology, 33, 53-56.
[16] Wiggans, R.G., Woolley, P.V., Macdonald, J.S., et al. (1978) Phase II Trial of Streptozotocin, Mitomycin-C and 5-Fluorouracil (SMF) in the Treatment of Advanced Pancreatic Cancer. Cancer, 41, 387-391. [Google Scholar] [CrossRef] 
[17] Carmichael, J. (1997) Clinical Response Benefit in Patients with Advanced Pancreatic Cancer. Role of Gemcitabine. Digestion, 58, 503-507. [Google Scholar] [CrossRef] [PubMed]
[18] 郭双双, 王羽, 杨琼, 等. 吉西他滨联合5-FU或卡培他滨与吉西他滨单药治疗晚期胰腺癌对比的Meta分析[J]. 循证医学, 2006, 6(1): 42-47.
[19] Novarino, A., Chiappino, I., Bertelli, G.F., et al. (2004) Phase II Study of Cisplatin, Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer. Annals of Oncology, 15, 474-477. [Google Scholar] [CrossRef] [PubMed]
[20] Loehrer, P.J., Feng, Y., Cardenes, H., et al. (2011) Gemcitabine Alone versus Gemcitabine plus Radiotherapy in Patients with Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 29, 4105-4112. [Google Scholar] [CrossRef] 
[21] Ng, S.P. and Herman, J.M. (2018) Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. Cancers (Basel), 10, pii: E75. [Google Scholar] [CrossRef] [PubMed]
[22] Schellenberg, D., Goodman, K.A., Lee, F., et al. (2008) Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. In-ternational Journal of Radiation Oncology, Biology, Physics, 72, 678-686. [Google Scholar] [CrossRef] [PubMed]
[23] Mulvihill, S., Warren, R., Venook, A., et al. (2001) Safety and Feasibility of Injection with an E1B-55 kDa Gene-Deleted, Replication-Selective Adenovirus (ONYX-015) into Primary Carcinomas of the Pancreas: A Phase I Trial. Gene Therapy, 8, 308-315. [Google Scholar] [CrossRef] [PubMed]
[24] Duda, D.G., Sunamura, M. and Lefter, L.P. (2003) Restoration of SMAD4 by Gene Therapy Reverses the Invasive Phenotype in Pancreatic Adenocarcinoma Cells. Oncogene, 22, 6857-6864. [Google Scholar] [CrossRef] [PubMed]
[25] Xue, W., Chen, S.D., Yin, H., et al. (2014) CRISPR-Mediated Direct Mutation of Cancer Genes in the Mouse Live. Nature, 514, 380-384. [Google Scholar] [CrossRef] [PubMed]
[26] van Dyke, T. and Jacks, T. (2002) Cancer Modeling in the Modern Era: Progress and Challenges. Cell, 108, 135-144. [Google Scholar] [CrossRef] 
[27] Jaffee, E.M., Hruban, R.H., Biedrzycki, B., et al. (2001) Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. Journal of Clinical Oncology, 19, 145-156. [Google Scholar] [CrossRef] 
[28] Bernhardt, S.L., Gjertsen, M.K., Trachsel, S., et al. (2006) Te-lomerase Peptide Vaccination of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating Phase I/II Study. British Journal of Cancer, 95, 1474-1482. [Google Scholar] [CrossRef] [PubMed]
[29] Copper, I.S. (1963) Cryogenic Surgery: A New Method of Destruction or Extirpation of Benign or Malignant Tissues. The New England Journal of Medicine, 268, 743-749. [Google Scholar] [CrossRef] 
[30] Clarke, D.M., Baust, J.M., Van Buskirk, R.G., et al. (2004) Addition of Anticancer Agents Enhances Freezing-Induced Prostate Cancer Cell Death: Implications of Mitochondrial Involvement. Cryobiology, 49, 45-61. [Google Scholar] [CrossRef] [PubMed]
[31] 李波, 李敬东, 陈晓理, 等. 无法切除的胰腺癌的冷冻手术治疗(附44例报告) [J]. 中华肝胆外科杂志, 2004, 10(8): 523-525.
[32] Kovach, S.J., Hendrickson, R.J., Cappadona, C.R., et al. (2002) Cryoablation of Unresectable Pancreatic Cancer Surgery. Surgery, 131, 463-464. [Google Scholar] [CrossRef] [PubMed]
[33] Ma, Y., Zou, F., Xiong, J., et al. (2015) Effect of Matrine on HPAC Cell Migration by Down-Regulating the Expression of MT1-MMP via Wnt Signaling. Cancer Cell International, 15, 59. [Google Scholar] [CrossRef] [PubMed]
[34] Singh, K., Dong, Q., Shanmugam, T., et al. (2018) Tetrandrine Inhibits Deregulated Cell Cycle in Pancreatic Cancer Cells: Differential Regulation of p21Cip1/Waf1, p27Kip1 and Cyclin D1. Cancer Letters, 425, 164-173. [Google Scholar] [CrossRef] [PubMed]
[35] Von Hoff, D.D., Ervin, T., Arena, F.P., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. [Google Scholar] [CrossRef] 
[36] 谢铮铮, 梁瑶, 孙路路. 厄洛替尼联合吉西他滨治疗胰腺癌有效性和安全性的Meta分析[J]. 中国临床药理学杂志, 2016, 32(8): 746-748.
[37] Moore, M.J., Goldstein, D., Hamm, J., et al. (2007) Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1960-1966. [Google Scholar] [CrossRef] 

为你推荐